中国病理生理杂志2025，Vol.41Issue(2)：394-402,9.DOI:10.3969/j.issn.1000-4718.2025.02.023
伴1q21获得/扩增型多发性骨髓瘤的研究进展
Progress in 1q21 gain/amplification type multiple myeloma
摘要
Abstract
Multiple myeloma(MM),a common malignancy of plasma cells,remains an incurable disease de-spite significant therapeutic advancements.A defining characteristic of MM is the recurrent occurrence of cytogenetic ab-normalities,particularly the gains of chromosome 1q21(1q21+),which are among the most frequently observed anoma-lies in this condition,affecting approximately 40%of patients with newly diagnosed MM.While numerous studies have identified 1q21+as an independent prognostic marker linked to poor outcomes in MM,its prognostic significance continues to be debated.An increasing number of national and international prognostic stratification systems classify 1q21+as a high-risk factor;however,its predictive value remains contentious.Variations in 1q21 copy numbers significantly impact genomic instability,drug resistance,and the likelihood of early disease progression,highlighting its growing importance in clinical management strategies.Despite the availability of various therapeutic approaches,such as autologous hemato-poietic stem cell transplantation,immunomodulatory drugs,and proteasome inhibitors,the adverse prognostic implica-tions of 1q21+persist unresolved.This review will explore the latest advancements in understanding the 1q21+in MM,fo-cusing on its pathogenesis,prognostic relevance,and implications for clinical management.关键词
多发性骨髓瘤/核型/染色体1q21Key words
multiple myeloma/karyotype/chromosome 1q21分类
医药卫生引用本文复制引用
史镜铂,于丽明,郑伟,崔思远..伴1q21获得/扩增型多发性骨髓瘤的研究进展[J].中国病理生理杂志,2025,41(2):394-402,9.基金项目
山东省医药卫生科技发展计划项目(No.202303041540 （）
No.202203040256) （）
山东省中医药科技项目(No.M-2022153) （No.M-2022153）
